• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Trading Notes on 21 Stocks I Currently Own

Here are my takes on stocks in biotech and other companies I own right now.
By JAMES "REV SHARK" DEPORRE
Feb 10, 2020 | 02:12 PM EST
Stocks quotes in this article: AIMT, APLS, APPS, AUPH, AXSM, BHVN, BXRX, CHRS, DBVT, DDOG, ENDP, ENPH, FLGT, GOLD, INFN, INMD, INSG, KDMN, LOV, LUNA, MTEM

Periodically I run through various positions that I'm holding and think about my strategy. With the market extended and difficult to buy right now, this is a good time to review and contemplate how trades may develop:

Aimmune Therapeutics ( AIMT) : Watching for support to form while awaiting news of launch of peanut allergy treatment.
 
Apellis Pharmaceuticals ( APLS) : Breaking to new highs, looking for additions on pullbacks.
 
Digital Turbine ( APPS) : Earnings are set for Monday night. May present a trade on good numbers.

Aurinia Pharmaceuticals (AUPH) : Top pick. Waiting for catalysts.

Axsome Therapeutics (AXSM) : Good day trader. Setting up well for a test of recent highs.

Biohaven Pharmaceutical Holding (BHVN) : Taking a hit Monday, but other news coming soon that is more important

Baudax Bio (BXRX) : Food and Drug Administration decision coming very soon. Very thin trader.

Coherus Biosciences (CHRS) : Stock of the week. Extending well. Watching for additional entries on pullbacks.

DBV Technologies (DBVT) : Peanut allergy play finding support.

Datadog (DDOG) : Top pick. Basing near highs.

Endo International (ENDP) : Opioid settlement play. Continues to develop well.

Enphase Energy (ENPH) : Very extended going into earnings. Needs to reset.

Fulgent Genetics (FLGT) : Extended and needs consolidation.

Barrick Gold (GOLD) : In trading range. Waiting for precious metals to perk up.

Infinera (INFN) : Chip play. Holding 50-day. Big revenue grower. Watching for earnings.

Inmode Ltd. (INMD) : Top pick. Volatile in front of earnings.

Inseego Corp (INSG) : bouncing after a sharp drop. Looking for entry points. Earnings report may be soft.

Kadmon Holdings (KDMN) : Consolidating at the 50-day.

Lovesac Co. (LOV) : January effect play that is still bouncing. Very thin.

Luna Innovations (LUNA) : Setting up very nicely into earnings.

Molecular Templates (MTEM) : High level base forming.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, DePorre was long AIMT, APLS, AUPH, AXSM, BHVN, BXRX, CHRS, DBVT, DDOG, ENDP, ENPH, FLGT, GOLD, INFN, INMD, INSG, KDMN, LOV, MTEM

TAGS: Earnings | Investing | Stocks | Biotechnology | Pharmaceuticals

More from Stocks

The Psilocybin Patent Race Is On

Debra Borchardt
Mar 6, 2021 12:30 PM EST

It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.

The Challenge of Short Selling

James "Rev Shark" DePorre
Mar 6, 2021 10:00 AM EST

Short selling is a powerful tool, but it is not just the inverse of going long and requires a very different mindset to do it effectively.

Kass: There Are Many Reasons to Be a Bear

Doug Kass
Mar 6, 2021 8:15 AM EST

I believe the markets are headed lower - probably not in a straight line or as steep as the last few days, but in a saw tooth fashion lower.

Bounce Takes Some of the Sting Out of a Painful Week

James "Rev Shark" DePorre
Mar 5, 2021 4:51 PM EST

It is premature to declare that the worst is over, but the intensity of the selling will go a long way toward helping a bottom to form.

The Selloff in Twilio Could Extend Deeper Into March

Bruce Kamich
Mar 5, 2021 2:30 PM EST

TWLO could bounce in the short-run but avoid the long side for now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST GARY BERMAN

    The INDU and DIA

    FIBOCALL: The INDU index and the DIA The INDU ...
  • 10:44 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Challenge of Short-Selling"
  • 08:40 AM EST PAUL PRICE

    Recent Pick SpartanNash (SPTN) Raised Its Quarterly Payout by 3.9%

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login